Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1-2 % of the general population and is increasingly prevalent in older people, occuring in about 10 % of over 80 year olds.1 AF is associated with a variety of cardiovascular conditions. The arrhythmia is associated with a five-fold rise in stroke risk and frequently coexists with heart failure, both leading to a further increase in mortality. [2][3][4][5] About 15 % of strokes are attributed to underlying AF, and 50-60 % to documented cerebrovascular disease, but in about 25 % of patients who have ischaemic strokes, no aetiological factor is identified. Subclinical atrial fibrillation is often suspected to be the cause of stroke in these patients.3,6-8 A recent study with implantable cardiac monitors in survivors of ischaemic stroke has revealed that far more than expected instances of so-called "cryptogenic stroke" are associated with episodes of AF revealed by continuous ECG monitoring.9,10 Concomitant medical conditions have an additive effect on the perpetuation of AF by promoting a substrate that maintains AF. Conditions associated with AF are also markers for global cardiovascular risk and/or cardiac damage rather than simply causative factors.
11Altogether, AF causes a significant economic burden which has grown in recent decades and is expected to grow even further in the future with the increasing trend in AF prevalence and hospitalisations.
12-14
Asymptomatic AF and the Low Yield of Intermittent MonitoringAF can show in several clinical scenarios. Some patients may suffer so much that they seek specialist help to be relieved from the arrhythmia.
AbstractAtrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with stroke risk and a variety of cardiovascular conditions. AF early detection is of paramount importance, in order to define proper medical treatment. This can be challenging due to the often silent and intermittent nature of the rhythm disturbance. Long-term external ECG monitoring may be very helpful, but if less than fully continuous and of long duration it will be not reliable. For this reason continuous monitoring is of increased importance, and outcome measurements of AF treatment trials will be based on the AF burden detected by insertable cardiac monitors (ICM) or therapeutic devices such as pacemakers or ICDs, leading to the paradigm that the detection of AF in the presence of thromboembolic risk factors should be performed wherever possible in order to improve patients' chances.